EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark AVIDITY was filed as Word mark on 08/14/2020 at the European Union Intellectual Property Office.
It was registered as a trademark on 09/29/2022.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 018289185 |
| Application date | August 14, 2020 |
| Publication date | June 22, 2022 |
| Entry date | September 29, 2022 |
| Expiration date | August 14, 2030 |
Trademark owner
10578 Science Drive, Suite 125
92121 San Diego
US
92121 San Diego
US
Trademark representatives
Arne Jacobsens Allé 15
2300 Copenhagen S
DK
goods and services
5
Biological, medicinal and pharmaceutical preparations for medical purposes for accessing and treating human muscle tissue; biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-based therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases; biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-based therapeutics for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; diagnostic preparations, namely for sample preparation, modification and manipulation of cells as well as for labelling, separation, isolation, purification, amplification and/or analysis of natural or synthetic biopolymers, namely nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances for gene modification; oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders; oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders; oligonucleotide compounds for use in targeted gene silencing; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies; reagents for testing human blood and tissue to detect the presence of genetic diseases and disorders and reactions to therapies; oligonucleotides, antibodies, in-vitro diagnostics and control reagents for medical purposes, being kit components for testing human blood and tissue to detect the presence of genetic diseases and disorders and reactions to therapies; kits, containing primarily of reagents, oligonucleotides, in-vitro diagnostic preparations, control reagents, electronic or online manuals and/or instruments for biochemical, molecular biological and immunological testing for the presence of diseases and reactions to therapies
42
Conducting clinical trials in the fields of pharmaceuticals and biotechnology for treating muscle tissue for the treatment of genetic diseases and disorders; conducting clinical trials in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials of oligonucleotide-based therapeutics for the for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases; conducting clinical trials in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders related to genetic diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology, namely, consultancy for the treatment of genetic diseases and disorders; consultancy relating to pharmaceutical research and development, namely, consultancy for the treatment of genetic diseases and disorders; development of pharmaceutical preparations and medicines for targeting and treating muscle tissue for the treatment of genetic diseases and disorders; services for assessing the efficiency of pharmaceuticals in treating genetic diseases and disorders; testing of pharmaceuticals for the treatment of genetic diseases and disorders; providing information about the results of clinical trials for pharmaceutical products for treatment of genetic diseases and disorders; scientific research for medical purposes, namely, for accessing and treating muscle tissue for the treatment of genetic diseases and disorders; pharmaceutical product evaluation for treatment of genetic diseases and disorders; medical research laboratory services for accessing and treating muscle tissue for the treatment of genetic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals and clinical trials related to genetic diseases and disorders; research and development in the pharmaceutical and biotechnology fields, namely, research for accessing and treating muscle tissue for the treatment of genetic diseases and disorders; research and development in the pharmaceutical and biotechnology fields, namely, research and development of oligonucleotide-based therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases; research and development in the pharmaceutical and biotechnology fields, namely, research and development of oligonucleotide-based therapeutics for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; research and development for the use of oligonucleotides for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical and scientific research services for the use of oligonucleotide for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases; medical and scientific research services for the use of oligonucleotide for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; development of pharmaceutical preparations and medicines, namely, the development of oligonucleotide-based therapeutics for accessing and treating muscle tissue for the treatment of genetic diseases and disorders; scientific research and development related to genetic diseases and disorders; scientific investigations for medical purposes related to genetic diseases and disorders; research and development of oligonucleotide drug delivery platforms for use in the treatment of genetic diseases and disorders related to genetic diseases and disorders; research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders related to genetic diseases and disorders; research and development of oligonucleotide compounds for targeted gene silencing related to genetic diseases and disorders
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| February 29, 2024 | Change Representative, Published | ||
| March 10, 2022 | Transfer / Change of address, Registered |
ID: 11018289185